While anti-CTLA-4 has also been shown to modify the immune status of the tumor microenvironment 1, the intrinsic site of therapeutic action for anti-CTLA-4 in locally advanced metastatic cancers remains in the tumor draining LNs (TDLNs) where naïve T-cells are activated against tumor Ags. The gene discussed is CTLA4; the disease is metastatic malignant neoplasm.